The impact of medical comorbidity on acute treatment in major depressive disorder

Dan V. Iosifescu, Andrew A. Nierenberg, Jonathan E. Alpert, Megan Smith, Stella Bitran, Christina Dording, Maurizio Fava

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Objective: The authors investigated the impact of medical comorbidity on the acute phase of antidepressant treatment in subjects with major depressive disorder. Method: A total of 384 outpatients meeting DSM-III-R criteria for major depressive disorder enrolled in 8-week open treatment with fluoxetine, 20 mg/day. The authors used the Cumulative Illness Rating Scale to measure the burden of medical comorbidity and the 17-item Hamilton Rating Scale for Depression to assess changes in depressive symptoms. The outcome measures were response to treatment (≥50% reduction in score) and clinical remission (score ≤7 at the end of the trial). Results: Compared to responders to fluoxetine, nonresponders had significantly higher Cumulative Illness Rating Scale scores and a greater number of Cumulative Illness Rating Scale categories were endorsed. Compared to subjects who achieved remission with antidepressant treatment, those who did not achieve remission had significantly higher Cumulative Illness Rating Scale scores and a greater number of Cumulative Illness Rating Scale categories were endorsed (i.e., more organs were affected by medical illness). The final Hamilton depression scale score was directly correlated with the total Cumulative Illness Rating Scale score and the number of Cumulative Illness Rating Scale categories endorsed. Conclusions: The total burden of medical illness and the number of organ systems affected by medical illness had a significantly negative predictive value for clinical outcome in the acute phase of treatment in major depressive disorder.

Original languageEnglish (US)
Pages (from-to)2122-2127
Number of pages6
JournalAmerican Journal of Psychiatry
Volume160
Issue number12
DOIs
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Major Depressive Disorder
Comorbidity
Fluoxetine
Depression
Antidepressive Agents
Therapeutics
Cost of Illness
Diagnostic and Statistical Manual of Mental Disorders
Outpatients
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Iosifescu, D. V., Nierenberg, A. A., Alpert, J. E., Smith, M., Bitran, S., Dording, C., & Fava, M. (2003). The impact of medical comorbidity on acute treatment in major depressive disorder. American Journal of Psychiatry, 160(12), 2122-2127. https://doi.org/10.1176/appi.ajp.160.12.2122

The impact of medical comorbidity on acute treatment in major depressive disorder. / Iosifescu, Dan V.; Nierenberg, Andrew A.; Alpert, Jonathan E.; Smith, Megan; Bitran, Stella; Dording, Christina; Fava, Maurizio.

In: American Journal of Psychiatry, Vol. 160, No. 12, 12.2003, p. 2122-2127.

Research output: Contribution to journalArticle

Iosifescu, DV, Nierenberg, AA, Alpert, JE, Smith, M, Bitran, S, Dording, C & Fava, M 2003, 'The impact of medical comorbidity on acute treatment in major depressive disorder', American Journal of Psychiatry, vol. 160, no. 12, pp. 2122-2127. https://doi.org/10.1176/appi.ajp.160.12.2122
Iosifescu, Dan V. ; Nierenberg, Andrew A. ; Alpert, Jonathan E. ; Smith, Megan ; Bitran, Stella ; Dording, Christina ; Fava, Maurizio. / The impact of medical comorbidity on acute treatment in major depressive disorder. In: American Journal of Psychiatry. 2003 ; Vol. 160, No. 12. pp. 2122-2127.
@article{f075a88a665742a68d860ca3833b72f3,
title = "The impact of medical comorbidity on acute treatment in major depressive disorder",
abstract = "Objective: The authors investigated the impact of medical comorbidity on the acute phase of antidepressant treatment in subjects with major depressive disorder. Method: A total of 384 outpatients meeting DSM-III-R criteria for major depressive disorder enrolled in 8-week open treatment with fluoxetine, 20 mg/day. The authors used the Cumulative Illness Rating Scale to measure the burden of medical comorbidity and the 17-item Hamilton Rating Scale for Depression to assess changes in depressive symptoms. The outcome measures were response to treatment (≥50{\%} reduction in score) and clinical remission (score ≤7 at the end of the trial). Results: Compared to responders to fluoxetine, nonresponders had significantly higher Cumulative Illness Rating Scale scores and a greater number of Cumulative Illness Rating Scale categories were endorsed. Compared to subjects who achieved remission with antidepressant treatment, those who did not achieve remission had significantly higher Cumulative Illness Rating Scale scores and a greater number of Cumulative Illness Rating Scale categories were endorsed (i.e., more organs were affected by medical illness). The final Hamilton depression scale score was directly correlated with the total Cumulative Illness Rating Scale score and the number of Cumulative Illness Rating Scale categories endorsed. Conclusions: The total burden of medical illness and the number of organ systems affected by medical illness had a significantly negative predictive value for clinical outcome in the acute phase of treatment in major depressive disorder.",
author = "Iosifescu, {Dan V.} and Nierenberg, {Andrew A.} and Alpert, {Jonathan E.} and Megan Smith and Stella Bitran and Christina Dording and Maurizio Fava",
year = "2003",
month = "12",
doi = "10.1176/appi.ajp.160.12.2122",
language = "English (US)",
volume = "160",
pages = "2122--2127",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "12",

}

TY - JOUR

T1 - The impact of medical comorbidity on acute treatment in major depressive disorder

AU - Iosifescu, Dan V.

AU - Nierenberg, Andrew A.

AU - Alpert, Jonathan E.

AU - Smith, Megan

AU - Bitran, Stella

AU - Dording, Christina

AU - Fava, Maurizio

PY - 2003/12

Y1 - 2003/12

N2 - Objective: The authors investigated the impact of medical comorbidity on the acute phase of antidepressant treatment in subjects with major depressive disorder. Method: A total of 384 outpatients meeting DSM-III-R criteria for major depressive disorder enrolled in 8-week open treatment with fluoxetine, 20 mg/day. The authors used the Cumulative Illness Rating Scale to measure the burden of medical comorbidity and the 17-item Hamilton Rating Scale for Depression to assess changes in depressive symptoms. The outcome measures were response to treatment (≥50% reduction in score) and clinical remission (score ≤7 at the end of the trial). Results: Compared to responders to fluoxetine, nonresponders had significantly higher Cumulative Illness Rating Scale scores and a greater number of Cumulative Illness Rating Scale categories were endorsed. Compared to subjects who achieved remission with antidepressant treatment, those who did not achieve remission had significantly higher Cumulative Illness Rating Scale scores and a greater number of Cumulative Illness Rating Scale categories were endorsed (i.e., more organs were affected by medical illness). The final Hamilton depression scale score was directly correlated with the total Cumulative Illness Rating Scale score and the number of Cumulative Illness Rating Scale categories endorsed. Conclusions: The total burden of medical illness and the number of organ systems affected by medical illness had a significantly negative predictive value for clinical outcome in the acute phase of treatment in major depressive disorder.

AB - Objective: The authors investigated the impact of medical comorbidity on the acute phase of antidepressant treatment in subjects with major depressive disorder. Method: A total of 384 outpatients meeting DSM-III-R criteria for major depressive disorder enrolled in 8-week open treatment with fluoxetine, 20 mg/day. The authors used the Cumulative Illness Rating Scale to measure the burden of medical comorbidity and the 17-item Hamilton Rating Scale for Depression to assess changes in depressive symptoms. The outcome measures were response to treatment (≥50% reduction in score) and clinical remission (score ≤7 at the end of the trial). Results: Compared to responders to fluoxetine, nonresponders had significantly higher Cumulative Illness Rating Scale scores and a greater number of Cumulative Illness Rating Scale categories were endorsed. Compared to subjects who achieved remission with antidepressant treatment, those who did not achieve remission had significantly higher Cumulative Illness Rating Scale scores and a greater number of Cumulative Illness Rating Scale categories were endorsed (i.e., more organs were affected by medical illness). The final Hamilton depression scale score was directly correlated with the total Cumulative Illness Rating Scale score and the number of Cumulative Illness Rating Scale categories endorsed. Conclusions: The total burden of medical illness and the number of organ systems affected by medical illness had a significantly negative predictive value for clinical outcome in the acute phase of treatment in major depressive disorder.

UR - http://www.scopus.com/inward/record.url?scp=3142684252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142684252&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.160.12.2122

DO - 10.1176/appi.ajp.160.12.2122

M3 - Article

VL - 160

SP - 2122

EP - 2127

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 12

ER -